ライフサイエンスコーパス: pancreatic neuroendocrine tumor

1 ing the hypothesis of a calcitriol producing pancreatic neuroendocrine tumor.

2 ing the hypothesis of a calcitriol-producing pancreatic neuroendocrine tumor.

3 CT were falsely positive in 1 nonfunctioning pancreatic neuroendocrine tumor.

4 nderance of PDX1+ somatostatinoma, a type of pancreatic neuroendocrine tumor.

5 ted findings: gastrointestinal polyposis and pancreatic neuroendocrine tumor.

6 verproduction-induced hypercalcemia due to a pancreatic neuroendocrine tumor.

7 ted, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors.

8 nism in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors.

9 ould be independent prognostic biomarkers of pancreatic neuroendocrine tumors.

10 sk of lymph node metastases in patients with pancreatic neuroendocrine tumors.

11 n the diagnosis, prognosis, and treatment of pancreatic neuroendocrine tumors.

12 able tool in the diagnosis and management of pancreatic neuroendocrine tumors.

13 er the last year in EUS in the evaluation of pancreatic neuroendocrine tumors.

14 peutic EUS interventions in the treatment of pancreatic neuroendocrine tumors.

15 utility of EUS in the clinical management of pancreatic neuroendocrine tumors.

16 trinomas comprise the majority of functional pancreatic neuroendocrine tumors.

17 future multi-institutional investigations on pancreatic neuroendocrine tumors.

18 iagnosis, imaging, treatment, and staging of pancreatic neuroendocrine tumors.

19 f rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors.

20 h metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors.

21 studies [40%] vs 11 studies [20%]; P = .02; pancreatic neuroendocrine tumors, 32 studies [51%] vs 16

22 enocarcinoma; pancreatic cystic lesions; and pancreatic neuroendocrine tumors, aiding in early diagno

23 From a prospective database of pancreatic neuroendocrine tumors, all patients with live

24 ents were conducted in mantle cell lymphoma, pancreatic neuroendocrine tumors and astrocytomas.

25 stations include renal carcinomas and cysts, pancreatic neuroendocrine tumors and cysts, pheochromocy

26 The UPR is upregulated in pancreatic neuroendocrine tumors and its inhibition sign

27 val among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with

28 g parathyroid neoplasia, pituitary adenomas, pancreatic neuroendocrine tumors, and carcinoids.

29 Prognostic biomarkers for the pancreatic neuroendocrine tumors are needed.

30 Pancreatic neuroendocrine tumors are rare neoplasms ofte

31 mone/peptide secreted), calcitriol secreting pancreatic neuroendocrine tumors are very rare.

32 Intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumor biology affect patient o

33 ther targeting IFNgamma and/or TNFalpha into pancreatic neuroendocrine tumors can alleviate immune su

34 itro accumulation experiments with the human pancreatic neuroendocrine tumor cell line BON-1 were per

35 Here, using paediatric glioma and pancreatic neuroendocrine tumor cell lines, we identify

36 cent information and advancements concerning pancreatic neuroendocrine tumor diagnosis, imaging chara

37 Gastro-entero-pancreatic neuroendocrine tumors (GEPNETs) are increasin

38 One patient with a pancreatic neuroendocrine tumor had a minor response and

39 tatic spread among patients with early-stage pancreatic neuroendocrine tumors has not been well estab

40 y altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality.

41 ided by both cancer cells and macrophages in pancreatic neuroendocrine tumors in humans and mice.

42 NETs, triggers the development of high-grade pancreatic neuroendocrine tumors in mice.

43 -Met is upregulated in lymphatics in or near pancreatic neuroendocrine tumors in RIP-Tag2 transgenic

44 antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies

45 gnostic significance of specific proteins in pancreatic neuroendocrine tumors including insulinoma.

46 Although rare, a thorough understanding of pancreatic neuroendocrine tumors is essential for all ph

47 Survival in patients with carcinoid and pancreatic neuroendocrine tumors is significantly better

48 usly treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear.

49 Sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against c

50 ting cathepsin B (CtsB) and CtsS in a murine pancreatic neuroendocrine tumor model.

51 ords of patients with carcinoid (n = 84) and pancreatic neuroendocrine tumors (n = 69) managed at our

52 Controversy remains over whether small pancreatic neuroendocrine tumors need to be surgically r

53 PURPOSE No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after

54 ival by 6.4 months in patients with advanced pancreatic neuroendocrine tumors (NET) compared with pla

55 Pancreatic neuroendocrine tumors (NETs) are rare neoplas

56 ced its first TNM staging classification for pancreatic neuroendocrine tumors (NETs) derived from the

57 Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatme

58 Patients with inoperable or unresectable pancreatic neuroendocrine tumors (NETs) have limited tre

59 Although pancreatic neuroendocrine tumors (NETs) in von Hippel-Li

60 ntributing to development and maintenance of pancreatic neuroendocrine tumors (NETs), with special re

61 anding of the pathogenesis of gastrinoma and pancreatic neuroendocrine tumors, new prognostic classif

62 Nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs) are often

63 ine neoplasms in pancreas are non-functional pancreatic neuroendocrine tumors (NF-PanNETs), which exh

64 Patients with nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) have poorer

65 udopapillary neoplasms, cystic variations of pancreatic neuroendocrine tumors, pancreatic ductal aden

66 Derived from endocrine cells, pancreatic neuroendocrine tumors (PanNET) universally hy

67 erogeneity modulated by PDGF-DD signaling in pancreatic neuroendocrine tumors (PanNET).

68 reatic ductal adenocarcinoma (PDAC, n = 58), pancreatic neuroendocrine tumors (PanNET, n = 42), intra

69 rs; however, its specific functions in human pancreatic neuroendocrine tumors (PanNETs) and spontaneo

70 Pancreatic neuroendocrine tumors (PanNETs) are a heterog

71 Pancreatic neuroendocrine tumors (PanNETs) are a rare bu

72 Pancreatic neuroendocrine tumors (PanNETs) are a relativ

73 Pancreatic neuroendocrine tumors (PanNETs) are a type of

74 Pancreatic neuroendocrine tumors (PanNETs) are rare mali

75 e key molecular alterations in small primary pancreatic neuroendocrine tumors (PanNETs) associated wi

76 g tumorigenesis and malignant progression of pancreatic neuroendocrine tumors (PanNETs) in a genetica

77 Efforts to model human pancreatic neuroendocrine tumors (PanNETs) in animals ha

78 Management of localized well-differentiated pancreatic neuroendocrine tumors (panNETs) is controvers

79 Improving the management of metastasis in pancreatic neuroendocrine tumors (PanNETs) is critical,

80 mutations of these genes are common in human pancreatic neuroendocrine tumors (PanNETs), we examined

81 rence following pancreatectomy for localized pancreatic neuroendocrine tumors (PanNETs).

82 schemas are utilized after resection of all pancreatic neuroendocrine tumors (PanNETs).

83 time to tumor progression was 7.7 months in pancreatic neuroendocrine tumor patients and 10.2 months

84 One-year survival rate was 81.1% in pancreatic neuroendocrine tumor patients and 83.4% in ca

85 rt, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients.

86 The incidence of pancreatic neuroendocrine tumor (PNET) is increasing, an

87 xysterol 24-hydroxycholesterol (24S-HC) in a pancreatic neuroendocrine tumor (pNET) model commonly us

88 AC), whereas tumor burden was reduced in the pancreatic neuroendocrine tumor (PNET) model, the latter

89 ncreatic ductal adenocarcinoma (PDAC) and in pancreatic neuroendocrine tumor (PNET), respectively.

90 intrapancreatic accessory spleens (IPAS) and pancreatic neuroendocrine tumor (pNET).

91 potential prognostic factor in patients with pancreatic neuroendocrine tumor (pNET).

92 L/6 (B6) background develop both noninvasive pancreatic neuroendocrine tumors (PNET) and invasive car

93 Pancreatic neuroendocrine tumors (PNET) have a poorly de

94 Pancreatic neuroendocrine tumors (pNET), also known as i

95 Pancreatic neuroendocrine tumors (pNETs) are a rare and

96 Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and ge

97 Pancreatic neuroendocrine tumors (PNETs) are rare tumors

98 Management of pancreatic neuroendocrine tumors (PNETs) associated with

99 Most pancreatic neuroendocrine tumors (PNETs) do not produce

100 olecule tyrosine inhibitor sunitinib in both pancreatic neuroendocrine tumors (PNETs) in RIP-Tag2 mic

101 Pancreatic neuroendocrine tumors (PNETs) may evolve and

102 Pancreatic neuroendocrine tumors (PNETs), although rare,

103 Epigenetic regulation is a key driver of pancreatic neuroendocrine tumors (PNETs), yet the interp

104 ctivated AKT/mTOR signaling is a hallmark of pancreatic neuroendocrine tumors (PNETs).

105 cRNA) MEG3 is significantly downregulated in pancreatic neuroendocrine tumors (PNETs).

106 There are few effective therapies for pancreatic neuroendocrine tumors (PNETs).

107 th tumor grade and liver metastasis in human pancreatic neuroendocrine tumors (PNETs).

108 CT scanning parameters for patients with pancreatic neuroendocrine tumors (PNETs; 124 patients an

109 s (PPV, 100%; NPV, 98%), and 68% and 98% for pancreatic neuroendocrine tumors (PPV, 85%; NPV, 95%), r

110 19% among patients with extrapancreatic and pancreatic neuroendocrine tumors, respectively, as compa

111 ing malignancy due to a calcitriol-producing pancreatic neuroendocrine tumor, responding to peptide r

112 served in a highly angiogenic mouse model of pancreatic neuroendocrine tumor RIP-Tag2.

113 sent study, 12 gastrinoma and nonfunctioning pancreatic neuroendocrine tumor specimens were evaluated

114 enome and tumor diameter-based algorithm for pancreatic neuroendocrine tumor surveillance may potenti

115 re examined in RIP-Tag2 transgenic mice with pancreatic neuroendocrine tumors that developed spontane

116 ors) are the most common type of functioning pancreatic neuroendocrine tumors that occur sporadically

117 In the cohort of 95 patients with pancreatic neuroendocrine tumors, the median progression

118 m Lu 177 after cremation of a patient with a pancreatic neuroendocrine tumor treated with the radiois

119 evaluate the dose-response relationship for pancreatic neuroendocrine tumors treated with PRRT using

120 24 lesions in 24 patients with metastasized pancreatic neuroendocrine tumors treated with repeated c

121 expression of UCH-L1 and alpha-internexin in pancreatic neuroendocrine tumors was significantly assoc

122 linger et al reported 2 female patients with pancreatic neuroendocrine tumors, WDS, and achlorhydria.

123 creatic neuroendocrine tumors and those with pancreatic neuroendocrine tumors - who had received pept

124 omen and ultrasound guided biopsy revealed a pancreatic neuroendocrine tumor with multifocal liver me

125 mutations exhibited interval growth, whereas pancreatic neuroendocrine tumors with loss of heterozygo

126 ad advanced, low-grade or intermediate-grade pancreatic neuroendocrine tumors with radiologic progres